EN DE

Kromek Group (KMK) Fair Value & Analysis

Technology · GB · Market cap 53.1M GBX

KG Kromek Group KMK · LSE
Price£0.0810
Fair Value£0.1045
Upside+29.0%
Quality68/100
Watch Kromek Group for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 33.0% net margin
Low debt · generates free cash flow
Ranks above peers (13/13)
Wide moat 80/100
Evidence: High Range £0.0883 – £0.1288 Share as image

Fair value as of: Jul 18, 2026

From 24 valuation models · updated 23 days ago

Fair value updated Jul 18, 2026, revised from £0.1030 to £0.1045 (+1.5%) since Jun 26, 2026. Share price −0.9% over the past month.

A solid business, screening 29% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (£0.0883). The market is more pessimistic than our downside scenario.
  • Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

£0.2001 £0.0310 Fair Value £0.1045 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

60‑month range £0.0310 – £0.2001 · fair‑value band £0.0883 – £0.1288 · the £0.0810 price screens below the £0.1045 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Kromek Group (KMK) currently trades at £0.0810, while our model-based Fair Value estimate is £0.1045, implying the stock looks roughly 29.0% undervalued today. The Quality Score stands at 68/100 (solid quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Kromek Group generated revenue of £37.8M at a net margin of 33.0%. It earns a return on equity of 25.1%. Net debt stands at £2.3M. The stock trades on a trailing P/E of 4.4. Fundamentals as of Jul 18, 2026

Our scenario range runs from £0.0883 (bear case) to £0.1288 (bull case); at £0.0810, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Technology peers we cover trades at -45% fair-value upside, at 29%, KMK screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF £0.2500 £0.4200 £0.6800 80
Rev-Margin DCF £0.1400 £0.2100 £0.3000 74
ROIC Compounder £0.0500 £0.0500 £0.0600 72
All 24 models by family
DCF Models
FCF DCF £0.2600 £0.4000 £0.7300 38
Owner Earnings £0.1300 £0.2500 £0.4300 31
5Y Revenue Exit £0.1400 £0.2100 £0.3200 39
5Y EBITDA Exit £0.1800 £0.3000 £0.4700 41
5Y P/E Exit £0.1500 £0.2400 £0.3400 38
10Y Revenue Exit £0.1800 £0.2700 £0.3900 36
10Y EBITDA Exit £0.2000 £0.3300 £0.5300 37
10Y P/E Exit £0.1900 £0.2800 £0.4300 35
Earnings-Based
Graham-Dodd £0.0400 £0.2500 £0.3500 54
Lynch FV £0.0700 £0.1000 £0.1300 50
PEG = 1.0 £0.0700 £0.1000 £0.1300 46
EPV £0.0500 £0.0500 £0.0600 59
Multiples
P/E Multiple £0.0900 £0.1100 £0.1400 63
P/S Multiple £0.0700 £0.1000 £0.1200 58
P/B Multiple £0.0700 £0.1000 £0.1200 55
EV/EBIT £0.1000 £0.1300 £0.1600 53
EV/EBITDA £0.1400 £0.1900 £0.2300 54
EV/Revenue £0.0700 £0.1000 £0.1200 43
Asset-Based
NCAV (Graham) £0.0400 £0.0500 £0.0800 50
Growth DCF
Growth DCF £0.2500 £0.4200 £0.6800 80
Rev-Margin DCF £0.1400 £0.2100 £0.3000 74
Economic Profit
Residual Income £0.0600 £0.0600 £0.0600 61
ROIC Compounder £0.0500 £0.0500 £0.0600 72
Growth Earnings
Growth-Adj P/E £0.1000 £0.1400 £0.1800 68

Widest divergence: DCF Models (£0.2700) versus Asset-Based (£0.0500). Highest evidence: Growth DCF (80).

Notify me when KMK reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 37.8M GBX
Revenue growth (YoY) +308%
Net margin 33.0%
Return on equity 25.1%
Free cash flow 15.7M GBX FY2025
P/E ratio 4.1
More key figures
Operating margin 21.3%
EPS (TTM) £0.0200
Net debt 2.3M GBX FY2025

Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 65 · Market factors (momentum, volatility) 45

Profitability 45
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 18
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 73
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets.

Full company description

Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets. It offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology for gamma-ray and neutron detection. The company also provides advanced imaging products, including CZT gamma detectors for SPECT imaging, CZT bone mineral densitometry detectors, D-Matrix gamma ray imager, and photon-counting spectral CT systems. In addition, it offers products and components for the security and defence markets, including UAV radiation mapping drones, alpha beta probes, radiation detectors, gamma and neutron detectors, D5 RIID, backpack with radiation detection, static node, tactical deployment detector charging station, and vehicle mounted radiation detector, as well as a range of gamma spectroscopy software that enables specialized analysis of samples. Further, the company provides CZT imaging research development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array for laboratory and research imaging; and engages in the scientific research and development activities. It sells its products through distributors, OEMs, and direct sales. The company has operations in the United Kingdom, North America, Asia, Europe, and internationally. The company was founded in 2003 and is headquartered in Sedgefield, the United Kingdom.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Kromek Group reported revenue of £26.5M in FY2025 versus £10.4M in FY2021, a compound +26.5%/yr. Reported net income was £3.8M in FY2025.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
£26.5M
Latest YoY
+36.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+30.0%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+15.1%
Avg. growth/yr (14Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+20.9%
Revenue +26.5%/yr
FY21 £10.4M
FY22 £12.1M
FY23 £17.3M
FY24 £19.4M
FY25 £26.5M
Net income
FY21 −£5.4M
FY22 −£4.9M
FY23 −£6.1M
FY24 −£3.3M
FY25 £3.8M

Watch KMK: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Kromek Group Fair Value". https://www.fairvalue-calculator.com/stock/KMK

Peer Group

Scientific & Technical Instruments · 161 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside +24% · Top 25%
Return on equity (TTM) 25% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 33% · Top 25%
Operating margin (TTM) 21% · Top 25%
Revenue growth 308% · Top 25%
Debt / equity 0.01× · Lower than median

Valuation Multiples vs Scientific & Technical Instruments median · lower = cheaper

P/E (TTM) 4.1× · Cheaper than 75% of peers
P/B 1.37× · Cheaper than median
P/S (TTM) 1.89× · Cheaper than median
P/FCF 4.6× · Cheaper than median
EV/EBITDA 4.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 65 · sector 0
FUTURE 100 · sector 34
PAST 100 · sector 25
HEALTH 100 · sector 98
DIVIDEND 0 · sector 24

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
Keysight Technologies, Inc KEYS $315.90 $84.16 -73%
Garmin Ltd GRMN $241.76 $146.67 -39%
Teledyne Technologies Incorporated TDY $635.52 $367.58 -42%
Chroma ATE Inc 2360 1,905 TWD 286.15 TWD -85%
Hexagon AB HEXAB kr 80.10 kr 52.93 -34%
MKS Inc MKSI $324.69 $77.46 -76%
AVIC Chengdu Aircraft Company 302132 ¥52.91 ¥34.47 -35%
Fortive Corporation FTV $61.78 $33.84 -45%
Trimble Inc TRMB $52.72 $24.47 -54%
Cognex Corporation CGNX $64.07 $13.75 -79%

Compare Kromek Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Kromek Group (KMK) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of £0.1045 versus a price of £0.0810, about +29% (undervalued).
What is the fair value of KMK?
Our model-based fair value for Kromek Group is £0.1045 (as of Jul 18, 2026), built from audited fundamentals. The current price is £0.0810.
What is the quality score of KMK?
Kromek Group has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Kromek Group (KMK)?
Kromek Group reported trailing-twelve-month revenue of about £37.8M (latest available figure, as of Jul 18, 2026).
What is the net profit margin of KMK?
The net profit margin of Kromek Group is about 33.0%, meaning it keeps roughly 33.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Kromek Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.